uniQure QURE EBITDA

EBITDA at other companies

Sarepta Therapeutics, Inc.SRPT

$23.7M-81.3%

Taysha Gene Therapies, Inc.TSHA

-$43.19M-104%

PTC TherapeuticsPTCT

$60.37M-93.8%

Design Therapeutics, Inc.DSGN

-$19.55M+3.5%

Candel Therapeutics, Inc.CADL

-$16.14M-105%

RegenxbioRGNX

$33.02M+156%

FAQ

What is uniQure's EBITDA?

uniQure (QURE) reported EBITDA of -$47.3M in Q2 2026.

How has uniQure's EBITDA changed year-over-year?

uniQure's EBITDA decreased by 17.5% year-over-year, from -$40.24M to -$47.3M.

What is the long-term trend for uniQure's EBITDA?

Over 4 years (2021 to 2025), uniQure's EBITDA has grown at a -14.4% compound annual growth rate (CAGR), from $317.92M to -$170.59M.

What does EBITDA mean?

Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.